,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2016', 'fs': 'Jan 2016', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbP2AR'}, 'Id': 'a0POZ00000R5cbP2AR', 'Event_Date__c': '2016-01-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jan 2016', 'Status_History__c': 'a132P000000Ar3aQAC'}, 'change': None}]",Jan 2016,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Committee recommended brentuximab vedotin be declined for the treatment of:  relapsed refractory HL, after 2 or more cycles of chemotherapy and ineligible for auto- SCT.  relapsed refractory HL prior to auto-SCT.   relapsed refractory HL after auto-SCT and not as a bridge to allo-SCT.   relapsed refractory HL after allo-SCT.     The Committee recommended brentuximab vedotin be funded with low priority for the treatment of:  relapsed refractory HL after auto-SCT as a bridge to allo-SCT.  relapsed refractory sALCL after auto-SCT as a bridge to allo-SCT.    The Committee deferred making a recommendation regarding relapsed refractory sALCL pending publication of the ECHELON-2 trial.     The Committee recommended that the application be referred to the Cancer Treatments Subcommittee for advice regarding how to define patients who are eligible for SCT and development of Special Authority criteria.', 'fs': 'The Committee recommended brentuximab vedotin be declined for the treatment of:  relapsed refractory HL, after 2 or more cycles of chemotherapy and ineligible for auto- SCT.  relapsed refractory HL prior to auto-SCT.   relapsed refractory HL after auto-SCT and not as a bridge to allo-SCT.   relapsed refractory HL after allo-SCT.     The Committee recommended brentuximab vedotin be funded with low priority for the treatment of:  relapsed refractory HL after auto-SCT as a bridge to allo-SCT.  relapsed refractory sALCL after auto-SCT as a bridge to allo-SCT.    The Committee deferred making a recommendation regarding relapsed refractory sALCL pending publication of the ECHELON-2 trial.     The Committee recommended that the application be referred to the Cancer Treatments Subcommittee for advice regarding how to define patients who are eligible for SCT and development of Special Authority criteria.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2016', 'fs': 'Aug 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbQ2AR'}, 'Id': 'a0POZ00000R5cbQ2AR', 'Event_Date__c': '2016-08-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Committee recommended brentuximab vedotin be declined for the treatment of:  relapsed refractory HL, after 2 or more cycles of chemotherapy and ineligible for auto- SCT.  relapsed refractory HL prior to auto-SCT.   relapsed refractory HL after auto-SCT and not as a bridge to allo-SCT.   relapsed refractory HL after allo-SCT.     The Committee recommended brentuximab vedotin be funded with low priority for the treatment of:  relapsed refractory HL after auto-SCT as a bridge to allo-SCT.  relapsed refractory sALCL after auto-SCT as a bridge to allo-SCT.    The Committee deferred making a recommendation regarding relapsed refractory sALCL pending publication of the ECHELON-2 trial.     The Committee recommended that the application be referred to the Cancer Treatments Subcommittee for advice regarding how to define patients who are eligible for SCT and development of Special Authority criteria.', 'Formatted_Date__c': 'Aug 2016', 'Status_History__c': 'a132P000000ArAjQAK'}, 'change': None}, {'Summary': {'s': 'Multiple recommendations:     1. The Subcommittee recommended that brentuximab vedotin for the treatment CD30-positive Hodgkin&#39;s lymphoma which has relapsed after two or more lines of chemotherapy for patients who are ineligible for autologous stem cell transplant be funded with a high priority subject to Special Authority criteria.     2. The Subcommittee recommended that brentuximab vedotin for the treatment CD30-positive Hodgkin&#39;s lymphoma post autologous stem cell transplant, be funded with a high priority subject to Special Authority criteria    3. The Subcommittee recommended that brentuximab vedotin for the second line treatment of CD30-positive systemic anaplastic large-cell lymphoma be funded with a medium priority subject to Special Authority criteria', 'fs': 'Multiple recommendations:     1. The Subcommittee recommended that brentuximab vedotin for the treatment CD30-positive Hodgkin&#39;s lymphoma which has relapsed after two or more lines of chemotherapy for patients who are ineligible for autologous stem cell transplant be funded with a high priority subject to Special Authority criteria.     2. The Subcommittee recommended that brentuximab vedotin for the treatment CD30-positive Hodgkin&#39;s lymphoma post autologous stem cell transplant, be funded with a high priority subject to Special Authority criteria    3. The Subcommittee recommended that brentuximab vedotin for the second line treatment of CD30-positive systemic anaplastic large-cell lymphoma be funded with a medium priority subject to Special Authority criteria', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 21 September 2018.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 21 September 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbR2AR'}, 'Id': 'a0POZ00000R5cbR2AR', 'Event_Date__c': '2018-09-21', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 21 September 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'Multiple recommendations:     1. The Subcommittee recommended that brentuximab vedotin for the treatment CD30-positive Hodgkin&#39;s lymphoma which has relapsed after two or more lines of chemotherapy for patients who are ineligible for autologous stem cell transplant be funded with a high priority subject to Special Authority criteria.     2. The Subcommittee recommended that brentuximab vedotin for the treatment CD30-positive Hodgkin&#39;s lymphoma post autologous stem cell transplant, be funded with a high priority subject to Special Authority criteria    3. The Subcommittee recommended that brentuximab vedotin for the second line treatment of CD30-positive systemic anaplastic large-cell lymphoma be funded with a medium priority subject to Special Authority criteria', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArXbQAK'}, 'change': None}, {'Summary': {'s': 'PTAC ratified subcommittee recommendations', 'fs': 'PTAC ratified subcommittee recommendations', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbS2AR'}, 'Id': 'a0POZ00000R5cbS2AR', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'PTAC ratified subcommittee recommendations', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArbDQAS'}, 'change': None}]",Aug 2016,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,,,False,False
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2019', 'fs': 'Jun 2019', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbT2AR'}, 'Id': 'a0POZ00000R5cbT2AR', 'Event_Date__c': '2019-06-03', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2019', 'Status_History__c': 'a132P000000ArghQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbU2AR'}, 'Id': 'a0POZ00000R5cbU2AR', 'Event_Date__c': '2020-01-24', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jan 2020', 'Status_History__c': 'a132P000000BPtVQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbV2AR'}, 'Id': 'a0POZ00000R5cbV2AR', 'Event_Date__c': '2021-06-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CuoTQAS'}, 'change': None}]",Jun 2019,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-20-proposal-to-fund-vedolizumab-for-inflammatory-bowel-disease-and-brentuximab-for-rare-lymphomas/', 'fs': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-20-proposal-to-fund-vedolizumab-for-inflammatory-bowel-disease-and-brentuximab-for-rare-lymphomas/', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbW2AR'}, 'Id': 'a0POZ00000R5cbW2AR', 'Event_Date__c': '2022-09-20', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Summary__c': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-20-proposal-to-fund-vedolizumab-for-inflammatory-bowel-disease-and-brentuximab-for-rare-lymphomas/', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E3yDQAS'}, 'change': None}]",Sep 2022,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbX2AR'}, 'Id': 'a0POZ00000R5cbX2AR', 'Event_Date__c': '2022-10-31', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Oct 2022', 'Status_History__c': 'a132P000000E9D0QAK'}, 'change': None}]",Oct 2022,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decision-to-fund-vedolizumab-for-inflammatory-bowel-disease-and-brentuximab-for-rare-lymphomas/', 'fs': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decision-to-fund-vedolizumab-for-inflammatory-bowel-disease-and-brentuximab-for-rare-lymphomas/', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2022', 'fs': 'Nov 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5cbY2AR'}, 'Id': 'a0POZ00000R5cbY2AR', 'Event_Date__c': '2022-11-17', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decision-to-fund-vedolizumab-for-inflammatory-bowel-disease-and-brentuximab-for-rare-lymphomas/', 'Formatted_Date__c': 'Nov 2022', 'Status_History__c': 'a132P000000EBpQQAW'}, 'change': None}]",Nov 2022,False,True
